The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV

Launched by XIJING HOSPITAL · Jan 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Palonosetron hydrochloride, which comes in capsule form, to see how safe and effective it is in preventing nausea and vomiting for patients undergoing chemotherapy that has a moderate risk of causing these side effects. The researchers are looking for patients with cancer who are between 18 and 75 years old and can tolerate chemotherapy. Participants must also have a good performance status, meaning they are able to carry out daily activities, and should not have any serious health issues that could interfere with the treatment or the trial.

If you decide to participate, you'll be part of a study that aims to improve the quality of life for patients receiving chemotherapy by reducing the unpleasant side effects of nausea and vomiting. Before joining, you'll need to undergo some routine tests to ensure your health is stable. The trial is currently recruiting participants, so if you meet the criteria and are interested, you can learn more about how to get involved. It’s important to discuss this option with your healthcare provider to see if it’s right for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • For patients with malignant tumors who can accept chemotherapy, the disease type is not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor treatment related nausea and vomiting prevention and treatment guidelines);
• • 18-75 years old, KPS score ≥ 70, and the expected survival time is more than 3 months;
• • Before treatment, ECG, blood routine test, liver and kidney functions and electrolytes were basically normal;
• • All patients signed the informed consent form
• Exclusion Criteria:
• • Patients with chemotherapy contraindications, patients allergic to 5-HT3RA, pregnant women and lactating women;
• • People with digestive tract obstruction; Patients with serious heart disease, liver and kidney disease and metabolic disorder; Patients suffering from epilepsy or using psychotropic and sedative drugs;
• • Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before treatment may have brain metastasis, intracranial hypertension, gastrointestinal obstruction, psychological abnormalities, etc.Patients with factors causing nausea and vomiting.